Astonea Labs share price
BSE: 544409Pharmaceuticals & BiotechnologySmall Cap
Last close ₹323.00down ₹1.00 (0.31%)
Share price at the BSE close on 19 Oct 2026. Previous close ₹324.00.
52-week range of traded prices to 19 Oct 2026
₹118.00Low, 24 Nov 2025₹369.00High, 18 Sep 2026
- Under BSE's long-term additional surveillance, stage I, on the list for 22 Oct 2026. The exchange puts a share here when its price has moved unusually, and trading in it carries extra conditions.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹340 Cr2,441st largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. The filing of 24 Jul 2026
- 75.2
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. The filing of 24 Jul 2026
- 5.9
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it, the company's own balance sheet from before it began consolidating; the two agree where both are first on record. The filing of 24 Jul 2026
- 12.0%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026. The filing of 24 Jul 2026
- 0.75
- Volume, BSEVolume. Shares traded on the last trading day.
- 1,000
Results
Standalone, as consolidated accounts are on record for only 1 of the last ten years; ₹ crore, the charts by years to March, the table by half year.Half-yearly results
Half year to Mar 2026, against the half year beforeFiled 30 May
- RevenueRevenue. The pill is the change in revenue against the half year before: this period's figure divided by that one's, less one, in per cent.
- ₹81 Crup 22.63%
- Net profitNet profit. The pill is the change in net profit against the half year before: this period's figure divided by that one's, less one, in per cent.
- ₹3.10 Crup 118.53%
- Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax.
- 3.8%
Revenue by year
Peak revenue ₹148 Cr, year to Mar 2026
Net profit by year, a loss in red
| ₹ crore | Sep 2024Filed 29 Aug | Mar 2025Filed 29 Aug | Sep 2025Filed 10 Nov | Mar 2026Filed 30 May |
|---|---|---|---|---|
| Revenue | 47.3 | 50.2 | 66.3 | 81.3 |
| Net profit | 2.1 | 3.2 | 1.4 | 3.1 |
| Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax. | 4.5% | 6.4% | 2.1% | 3.8% |
Standalone. The 4 half years from Sep 2024, the first on record. The latest is shaded.
Business segments
In the year to Mar 2026 the company reports one business segment, DRUGS, PHARMACEUTICALS AND COSMETICS, which carries all its revenue.
Peers and competitors
Pharmaceuticals, 216 listed companies, priced on 23 Oct 2026. The table lists the 8 companies closest to Astonea Labs in market cap. Astonea Labs's own figures are from its last trade, on 19 Oct 2026.
Where the company sits among the companies nearest its size
| Company | |||||||||
|---|---|---|---|---|---|---|---|---|---|
 Albert DavidALBERTDAVD | 436 | 19.3 | 1.1 | 16.1 | +11.4% | +258.5% | 5.8% | 4.1% | 0.65% |
 Jenburkt PharmaceuticalsJENBURPH | 384 | 11.7 | 2.0 | 8.1 | +9.1% | +1.2% | 17.8% | 19.2% | 2.38% |
 Medicamen BiotechMEDICAMEQ | 344 | – | 1.2 | 18.5 | +24.7% | – | – | 3.7% | 0.39% |
 Aarey Drugs & PharmaceuticalsAAREYDRUGS | 340 | – | – | – | −7.7% | – | – | 1.8% | 0.00% |
 Lyka LabsLYKALABS | 293 | – | 3.2 | – | −2.6% | – | −9.2% | −8.0% | 0.00% |
 Astal LaboratoriesASTALLTD | 279 | 28.7 | 0.9 | 19.3 | +122.7% | +4.4% | 5.4% | 4.2% | 0.00% |
 Ambalal Sarabhai EnterprisesAMBALALSA | 266 | 19.6 | 1.7 | 20.1 | +4.9% | +5.8% | 9.1% | 5.0% | 0.00% |
 Zenotech LaboratoriesZENOTECH | 246 | – | 2.6 | 61.1 | +4.6% | – | −2.6% | −3.9% | 0.00% |
Market cap in ₹ crore. Growth is the last twelve months against the twelve before. A figure is left empty where it would rest on a loss or the company has under a year of results on record. ROE is the shareholders' profit over their net worth. ROCE is profit before interest and tax over the whole group's net worth plus borrowings, as in the figures at the top of the page.
Latest announcements
Routine notices left out.Share news and announcements
Oct 2026
9 Oct · Intimation Regarding Change In The Corporate Identification Number (CIN) Of The Company Consequent Upon Alteration Of The Object Clause Of The Memorandum Of Association
8 Oct · Incorporation Of Proposed Subsidiary- Longevity Science Private Limited
Sep 2026
Astonea Labs share price by year
Each calendar year to 2025.Astonea Labs share price history
| Year | Close at year end | Change | Highest close | Lowest close |
|---|---|---|---|---|
| 2025 | 163.50 | – | 182.30 | 135.00 |
₹ per share, adjusted for splits and bonuses since. Change is on the close at the end of the year before. 2025 is from its first session, 3 Jun 2025.
Recent sessions
The last 10 trading days to 19 Oct 2026, as traded on BSE.
| Date | Open | High | Low | Close | Average price | Volume |
|---|---|---|---|---|---|---|
| 19 Oct 2026 | 323.00 | 323.00 | 323.00 | 323.00 | 323.00 | 1,000 |
| 12 Oct 2026 | 323.95 | 324.00 | 323.95 | 324.00 | 323.98 | 2,000 |
| 9 Oct 2026 | 316.35 | 324.00 | 316.35 | 324.00 | 319.16 | 4,000 |
| 6 Oct 2026 | 334.00 | 334.00 | 334.00 | 334.00 | 334.00 | 1,000 |
| 5 Oct 2026 | 335.00 | 335.00 | 335.00 | 335.00 | 335.00 | 1,000 |
| 1 Oct 2026 | 345.00 | 345.00 | 345.00 | 345.00 | 345.00 | 1,000 |
| 30 Sep 2026 | 348.15 | 348.15 | 348.15 | 348.15 | 348.15 | 1,000 |
| 25 Sep 2026 | 338.00 | 338.00 | 338.00 | 338.00 | 338.00 | 1,000 |
| 24 Sep 2026 | 333.00 | 333.00 | 333.00 | 333.00 | 333.00 | 1,000 |
| 23 Sep 2026 | 332.45 | 332.45 | 332.45 | 332.45 | 332.45 | 1,000 |
Prices in ₹ per share as traded, not adjusted.
Company details
- Legal name
- ASTONEA LABS LIMITED
- BSE code
- 544409
- ISIN
- INE0TG901011
- Industry
- Pharmaceuticals & Biotechnology
- Listed
- Jun 2025
- Face value
- ₹10
- CIN
- L24304CH2017PLC041482
- Corporate identity number, the registrar of companies' code for it